MADISON, Wis.--(BUSINESS WIRE)--Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food ...

SAN FRANCISCO (MarketWatch) -- AstraZeneca PLC said Monday that results from a one-year study show that patients taking its Symbicort single-inhaler therapy had fewer asthma attacks and required less ...

The U.S. Food and Drug Administration said yesterday that it has given approval for the first generic of the Symbicort inhaler to treat asthma and COPD. Symbicort is a combination of budesonide and ...

In the courtroom fracas over the patents on AstraZeneca’s multibillion-dollar inhaler Symbicort, Viatris and Kindeva Drug Delivery have toppled yet another intellectual property pillar. Still, ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

Taking medication the wrong way can make it less effective—or even useless. From inhalers to antibiotics, timing, technique, and food interactions matter more than most people realize. Learning the ...

AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.

The first generic version of Symbicort -- a metered-dose inhaler that combines the corticosteroid budesonide with the long-acting bronchodilator formoterol -- has been approved for asthma and chronic ...

After seeing four of its patents for its Symbicort tossed aside, AstraZeneca has gained a key victory in defense of its blockbuster inhaler. A federal court in West Virginia upheld the company’s claim ...

Add Yahoo as a preferred source to see more of our stories on Google. Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the ...